Anal Cancer Screening in MSM
HPV-Driven Anal Dysplasia, the ANCHOR Trial (2022), Anal Cytology & High-Resolution Anoscopy
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Screening modality (anal cytology, HRA); not a single FDA product
Reference only. Not medical advice.
What can go wrong
Screening procedures carry modest risks: HRA and biopsy can cause transient discomfort, minor bleeding, and rarely infection; treatment of HSIL (ablation, infrared coagulation, topical fluorouracil/imiquimod) may cause local pain, irritation, and recurrence requiring repeat sessions. The randomized benefit of screen-and-treat is best established in people with HIV aged 35 and older (the ANCHOR population), so screening decisions in lower-risk MSM are individualized. The main systemic limitation is the scarce supply of clinicians trained in high-resolution anoscopy, which constrains access. Anal symptoms should never be assumed benign without evaluation, since bleeding or a mass can signal invasive cancer.
This is something to take to a clinician. The Atlas can tell you what is known about anal cancer screening in msm in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Anal squamous cell carcinoma is driven by persistent infection with high-risk human papillomavirus (especially HPV-16), the same biology as cervical cancer. Incidence is markedly elevated in MSM, and highest in MSM living with HIV. The landmark ANCHOR trial (Palefsky et al., NEJM, 2022; NCT02135419) randomized 4,459 people with HIV aged 35 and older who had biopsy-proven anal high-grade squamous intraepithelial lesions (HSIL) to immediate treatment versus active monitoring; treating HSIL reduced progression to anal cancer by about 57 percent, providing the first randomized proof that screen-and-treat works. Screening tools are analogous to cervical screening: anal cytology (an 'anal Pap'), high-risk HPV testing, digital anorectal exam, and, for abnormal results, high-resolution anoscopy (HRA) with directed biopsy. HPV vaccination is primary prevention. Cross-links: sti-hpv, sti-hiv.
The 2022 ANCHOR trial provided the first randomized evidence that treating anal precancer prevents anal cancer in people with HIV.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Anal cytology (anal Pap)
- Cytologic sampling of the anal canal to detect dysplasia; abnormal results trigger HRA
- High-risk HPV testing
- Detects oncogenic HPV genotypes; used alone or with cytology for risk stratification
- Digital anorectal exam (DARE)
- Palpation to detect masses; cheap, available everywhere, and recommended even where HRA is not
- High-resolution anoscopy
- Magnified, stained visualization of the anal canal with directed biopsy of suspicious areas; the diagnostic standard
How it works
High-risk HPV oncoproteins E6 and E7 inactivate the p53 and Rb tumor suppressors in anal transition-zone epithelium, driving progression from low-grade (LSIL) to high-grade (HSIL) dysplasia and, in a subset, to invasive squamous cell carcinoma over years. The transformation zone of the anal canal is the principal site, paralleling the cervix. Screening detects HSIL before invasion; treatment (office-based ablation, infrared coagulation, electrocautery, or topical fluorouracil/imiquimod) removes the precancerous lesion to interrupt progression.
What ANCHOR did and did not settle
ANCHOR established that treating HSIL reduces cancer in people with HIV aged 35+, and it was stopped early for efficacy. What it did not directly establish is the optimal screening interval, the best single screening test, cost-effectiveness across all MSM subgroups, or identical benefit in HIV-negative MSM (who are higher-risk than the general population but lower-risk than those with HIV). A major real-world constraint is the limited supply of clinicians trained in high-resolution anoscopy, which is technically demanding; expanding screening hinges on training capacity. Post-ANCHOR guidance (e.g., consensus guidelines for screening people with HIV) now supports structured screening where HRA is available.
Safety in detail
- HRA and biopsy can cause transient discomfort, minor bleeding, and rarely infection
- Treatment (ablation/topical) may cause local pain, irritation, and recurrence requiring repeat sessions
- Screening benefit is best established in people with HIV aged 35+ (the ANCHOR population)
- Limited HRA-trained clinician supply restricts access in many regions
What people get wrong
Often saidAnal cancer is rare, so screening is unnecessary
ActuallyIt is uncommon in the general population but substantially elevated in MSM and highest in MSM with HIV. ANCHOR showed that in higher-risk groups, screen-and-treat reduces cancer.
Often saidThe HPV vaccine is only for cervical cancer in young women
ActuallyHPV vaccination prevents the oncogenic infections that cause anal (and oropharyngeal/penile) cancers; it is recommended for boys and men and is the primary-prevention complement to screening.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Anal cancer screening is modeled on cervical screening but lags it in evidence and infrastructure. Cytology plus high-risk HPV testing triages who needs HRA; DARE is the universally available minimum. Unlike cervical screening, anal screening lacks a fully standardized national program in most countries, and HRA capacity is the rate-limiting step.
What we do not know
- Optimal screening interval and test combination across MSM risk strata?
- Does screen-and-treat reduce anal cancer in HIV-negative MSM as it does in those with HIV?
- How to scale high-resolution anoscopy training to meet demand?
At a glance
- Driver
- Persistent high-risk HPV (esp. HPV-16)
- Highest risk
- MSM living with HIV
- ANCHOR result
- ~57% reduction in anal cancer with HSIL treatment
- ANCHOR size
- 4,459 randomized, age >=35, all with HIV
- Diagnostic gold standard
- High-resolution anoscopy (HRA) + biopsy
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Anal Cancer Screening in MSM. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Palefsky et al. (ANCHOR), NEJM2022
RCT in 4,459 people with HIV: treating anal HSIL reduced progression to anal cancer by ~57% vs active monitoring; trial stopped early for efficacy
Machalek et al., Lancet Oncology2012
Meta-analysis quantifying high anal HSIL/HPV prevalence and anal-cancer incidence in MSM, especially those with HIV
IANS / consensus screening guidelines2024
Post-ANCHOR risk-based guidance on whom to screen and how, prioritizing MSM with HIV